INDEPENDENT THINKING. WHOLE-FOOD LIVING.NO ANIMALS / NO OIL
THENANODIET
← THE STUDY LIBRARY

Narrative review / 2008

Curcumin is safe up to 12 g daily for 3 months in phase I trials and may have potential therapeutic roles across various chronic diseases.

This review summarizes research on curcumin, the active compound in turmeric. Preclinical studies suggest curcumin has antiproliferative, chemopreventive, and therapeutic potential across diverse conditions by modulating kinases, transcription factors, and cell cycle proteins. Pilot phase I clinical trials have shown curcumin to be safe even when consumed at a daily dose of 12 g for 3 months. Other clinical trials suggest a potential therapeutic role for curcumin in diseases including familial adenomatous polyposis, inflammatory bowel disease, ulcerative colitis, colon cancer, pancreatic cancer, hypercholesteremia, atherosclerosis, pancreatitis, psoriasis, chronic anterior uveitis, and arthritis.

Study type
Narrative review
Who was studied
Human clinical trial participants and preclinical models
What was measured
Curcumin safety, molecular mechanisms, and potential therapeutic roles

THE PAPER

Curcumin as "Curecumin": from kitchen to clinic.

Goel A, Kunnumakkara AB, Aggarwal BB. Biochem Pharmacol, 2008.

PubMed 17900536 ↗DOI 10.1016/j.bcp.2007.08.016 ↗

Heart & arteriesDiabetes & blood sugarCancerGut & microbiomeBrain & moodOther health

This note is written from the study's published abstract. It summarizes what the authors reported; it is not medical advice and does not replace reading the full paper.